Dr. Reddys Labs (RDY) Reports Q2 EPS of $0.27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dr. Reddy’s Q2 and H1 FY17 Financial Results
October 25, 2016 6:37 AM EDT
Q2 Revenues at Rs. 35.9 Bn
(QoQ growth: 11%)
Q2 EBITDA at Rs. 6.4 Bn
(17.9% of Revenues)
H1 Revenues at Rs. 68.2 Bn
(YoY decline: 12%)
H1 EBITDA at Rs. 10.4 Bn
(15.2% of Revenues)
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddys Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the second quarter and half year ended September 30, 2016 under International Financial Reporting Standards (IFRS).
Q2 FY17: Key Highlights
Revenues at Rs. 35.9 billion: QoQ growth: 11%... More